Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of infectious diseases
3.2.1.2 Expanding vaccination programs
3.2.1.3 Growing advancements in vaccine development
3.2.1.4 Robust government support & funding for vaccine development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with vaccine development
3.2.2.2 Stringent regulations for the approval
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Bacterial vaccine
5.3 Viral vaccine
Chapter 6 Market Estimates and Forecast, By Development, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Tissue culture
6.3 Embryonated eggs
6.4 Live animals
Chapter 7 Market Estimates and Forecast, By Mode of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Intranasal
Chapter 8 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Pediatric
8.3 Adult
Chapter 9 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Tuberculosis
9.3 Measles
9.4 Rotavirus
9.5 Yellow fever
9.6 Oral polio
9.7 Influenza
9.8 Other indications
Chapter 10 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Hospitals
10.2.1 Public
10.2.2 Private
10.3 Specialty clinics
10.4 Other end-users
Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
11.1 Key trends, by region
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Middle East and Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 Abbott
12.2 Bharat Biotech International Limited
12.3 Boehringer Ingelheim International GmbH
12.4 GlaxoSmithKline, plc.
12.5 Haffkine Biopharmaceutical Corporation Limited
12.6 HBI
12.7 Merck & Co.
12.8 Novartis Pharmaceuticals Corporation
12.9 Sanofi
12.10 Serum Institute of India Ltd.
12.11 Valneva SE
12.12 Zydus Group
